<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01651351</url>
  </required_header>
  <id_info>
    <org_study_id>471201</org_study_id>
    <nct_id>NCT01651351</nct_id>
  </id_info>
  <brief_title>GLASSIA Infusion Rate Study</brief_title>
  <official_title>A Phase 4 Double-Blind Study to Assess the Safety and Tolerability of Intravenous Administration of GLASSIA in Healthy Adult Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Baxalta now part of Shire</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shire</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study was to generate sufficient safety and tolerability information in
      support of an increase in the infusion rate of intravenous GLASSIA in the prescribing
      information from 0.04 to 0.2 mL/kg/min.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To achieve proper masking, 30 participants were randomly assigned to receive either GLASSIA
      at 0.04 mL/kg/min with a simultaneous administration of placebo (2.5% human albumin in normal
      saline) at 0.2 mL/kg/min (Cohort 1) or GLASSIA at 0.2 mL/kg/min with a simultaneous
      administration of placebo at 0.04 mL/kg/min (Cohort 2) on Day 1.

      Two weeks later (Day 15), the same participants received the second infusion with the
      opposite rate of GLASSIA infusion and the corresponding masking placebo infusion.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 31, 2012</start_date>
  <completion_date type="Actual">January 16, 2013</completion_date>
  <primary_completion_date type="Actual">January 16, 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Infusions Associated With a Reduction in Infusion Rate or Discontinuation of Infusion Due to an Adverse Event (Regardless of Adverse Event Causality Assessment)</measure>
    <time_frame>Day 1 and Day 15</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Infusions With Temporally Associated Adverse Events (AEs) That Began During or Within 1 Hour of Infusion Completion</measure>
    <time_frame>Within 1 hour of infusion completion</time_frame>
    <description>Number of infusions with temporally associated AEs with an onset time during or within 1 hour of infusion completion, regardless of causality assessment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Infusions With Temporally Associated Adverse Events (AEs) That Began During or Within 24 Hours of Completion of an Infusion</measure>
    <time_frame>Within 24 hours of the end of infusion</time_frame>
    <description>Number of infusions with temporally associated AEs with an onset time during or within 24 hours of infusion completion, regardless of causality assessment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Infusions With Temporally Associated Adverse Events (AEs) That Began During or Within 72 Hours of Completion of an Infusion</measure>
    <time_frame>Within 72 hours of the end of infusion</time_frame>
    <description>Number of infusions with temporally associated AEs with an onset time during or within 72 hours of infusion completion, regardless of causality assessment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Possibly or Probably Related Adverse Events (AEs) That Began During an Infusion</measure>
    <time_frame>Day 1 and Day 15</time_frame>
    <description>Number of AEs that occurred during an infusion and were deemed related to study product administration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Possibly or Probably Related Adverse Events That Occurred Between 72 Hours and 14 Days After Infusion</measure>
    <time_frame>72 hours post infusion to 14 days post infusion</time_frame>
    <description>Number of AEs that occurred between 72 hours and 14 day following an infusion and were deemed related to study product administration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Testing Positive for Hepatitis A Virus (HAV), Hepatitis B Virus (HBV), Hepatitis C Virus (HCV), Parvovirus B19 (PVB19) or Human Immunodeficiency Virus (HIV) Following Treatment With GLASSIA</measure>
    <time_frame>105 days</time_frame>
    <description>Number of participants with seroconversion</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Alpha1-antitrypsin Deficiency</condition>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Day 1:
GLASSIA at 0.04 mL/kg/min
Placebo at 0.2 mL/kg/min
Day 15:
GLASSIA at 0.2 mL/kg/min
Placebo at 0.04 mL/kg/min</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Day 1:
GLASSIA at 0.2 mL/kg/min
Placebo at 0.04 mL/kg/min
Day 15:
GLASSIA at 0.04 mL/kg/min
Placebo at 0.2 mL/kg/min</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Alpha1-proteinase inhibitor</intervention_name>
    <description>GLASSIA will be supplied as a sterile, non-pyrogenic, ready-to-use solution, in single dose 50 mL vials; for intravenous administration.</description>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_label>Cohort 2</arm_group_label>
    <other_name>GLASSIA</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo: Human albumin 2.5%</intervention_name>
    <description>Intravenous administration</description>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_label>Cohort 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female, 18 to 65 years of age inclusive, at the time of screening

          -  Body mass index (BMI) in the range of 19.0 to 32.0 kg/m2 (inclusive) and body weight
             &gt;= 50 kg at the time of screening

          -  Healthy subject with no clinical evidence of acute and/or chronic disease and no
             clinically significant abnormalities on hematology panel, clinical chemistry panel,
             urinalysis, or electrocardiogram (ECG) at the time of screening

          -  Negative drug screen test at screening. Subject must agree to refrain from heavy
             alcohol consumption (defined as more than 2 drinks per day on a regular basis) and use
             of narcotic drugs or illegal substances for at least 2 weeks prior to screening and
             throughout the course of the study. Subject must also agree to drug screen testing at
             the discretion of the investigator at any time during the course of the study.

          -  If female of childbearing potential, subject presents with a negative serum pregnancy
             test and agrees to employ adequate birth control measures for the duration of the
             study

          -  If male, the subject must agree to use an acceptable form of birth control throughout
             the study and for at least 90 days after dosing. Additionally, the subject must agree
             to abstain from sperm donation for 90 days after the last administration of
             investigational product.

          -  Subject is willing and able to comply with the requirements of the protocol

        Exclusion Criteria:

          -  Known history of OR positive serological evidence at the time of screening for
             hepatitis A virus (HAV), hepatitis B virus (HBV), hepatitis C virus (HCV), Parvovirus
             B19 (PVB19) or human immunodeficiency virus (HIV) type 1/2 infection

          -  Known history of hypersensitivity or adverse reactions (e.g. urticaria, breathing
             difficulty, severe hypotension, or anaphylaxis) following administration of blood or
             blood components

          -  Documented immunoglobulin A (IgA) deficiency (&lt;7 mg/dL at screening)

          -  Evidence of uncontrolled hypertension (systolic blood pressure of &gt;160 mm Hg, and/or
             diastolic blood pressure of &gt;100 mm Hg despite anti-hypertensive medications)

          -  Subject is nursing or intends to begin nursing during the course of the study

          -  Subject has participated in a clinical trial and has received an investigational
             product within 60 days prior to screening

          -  Subject has a planned medical procedure within the study period

          -  Any clinically significant medical, psychiatric, or cognitive illness or recreational
             drug/alcohol use that, in the opinion of the investigator, may impede the subject's
             ability to comply with the study procedures, pose increased risk to the subject's
             safety, or confound the interpretation of study results
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Leman Yel, MD</last_name>
    <role>Study Director</role>
    <affiliation>Baxter Healthcare Corporation</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Overland Park</city>
        <state>Kansas</state>
        <zip>66211</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 23, 2012</study_first_submitted>
  <study_first_submitted_qc>July 25, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 27, 2012</study_first_posted>
  <results_first_submitted>April 29, 2014</results_first_submitted>
  <results_first_submitted_qc>April 29, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 29, 2014</results_first_posted>
  <disposition_first_submitted>January 31, 2014</disposition_first_submitted>
  <disposition_first_submitted_qc>January 31, 2014</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">March 4, 2014</disposition_first_posted>
  <last_update_submitted>January 16, 2018</last_update_submitted>
  <last_update_submitted_qc>January 16, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 12, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>for this study</keyword>
  <keyword>volunteers</keyword>
  <keyword>Focus</keyword>
  <keyword>Condition:</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alpha 1-Antitrypsin Deficiency</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Protease Inhibitors</mesh_term>
    <mesh_term>Alpha 1-Antitrypsin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment was conducted in the U.S at 1 study site. The first participant was enrolled in July 2012.</recruitment_details>
      <pre_assignment_details>Thirty five healthy potential participants were enrolled at the clinical study site. Four were screen failures, and one was a back up participant who did not participate. Therefore, 30 participants were randomized.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Cohort 1</title>
          <description>Day 1:
GLASSIA at 0.04 mL/kg/min
Placebo at 0.2 mL/kg/min
Day 15:
GLASSIA at 0.2 mL/kg/min
Placebo at 0.04 mL/kg/min
Alpha1-proteinase inhibitor: GLASSIA will be supplied as a sterile, non-pyrogenic, ready-to-use solution, in single dose 50 mL vials; for intravenous administration.
Placebo: Human albumin 2.5%: Intravenous administration</description>
        </group>
        <group group_id="P2">
          <title>Cohort 2</title>
          <description>Day 1:
GLASSIA at 0.2 mL/kg/min
Placebo at 0.04 mL/kg/min
Day 15:
GLASSIA at 0.04 mL/kg/min
Placebo at 0.2 mL/kg/min
Alpha1-proteinase inhibitor: GLASSIA will be supplied as a sterile, non-pyrogenic, ready-to-use solution, in single dose 50 mL vials; for intravenous administration.
Placebo: Human albumin 2.5%: Intravenous administration</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Safety Analysis Set</population>
      <group_list>
        <group group_id="B1">
          <title>Cohort 1</title>
          <description>Day 1:
GLASSIA at 0.04 mL/kg/min
Placebo at 0.2 mL/kg/min
Day 15:
GLASSIA at 0.2 mL/kg/min
Placebo at 0.04 mL/kg/min
Placebo: Human albumin 2.5%: Intravenous administration</description>
        </group>
        <group group_id="B2">
          <title>Cohort 2</title>
          <description>Day 1:
GLASSIA at 0.2 mL/kg/min
Placebo at 0.04 mL/kg/min
Day 15:
GLASSIA at 0.04 mL/kg/min
Placebo at 0.2 mL/kg/min
Placebo: Human albumin 2.5%: Intravenous administration</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="15"/>
            <count group_id="B2" value="15"/>
            <count group_id="B3" value="30"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27" spread="8"/>
                    <measurement group_id="B2" value="29" spread="13"/>
                    <measurement group_id="B3" value="28" spread="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Infusions Associated With a Reduction in Infusion Rate or Discontinuation of Infusion Due to an Adverse Event (Regardless of Adverse Event Causality Assessment)</title>
        <time_frame>Day 1 and Day 15</time_frame>
        <population>Safety Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>GLASSIA at 0.04 mL/kg/Min + Placebo at 0.2 mL/kg/Min</title>
          </group>
          <group group_id="O2">
            <title>GLASSIA at 0.2 mL/kg/Min + Placebo at 0.04 mL/kg/Min</title>
          </group>
        </group_list>
        <measure>
          <title>Number of Infusions Associated With a Reduction in Infusion Rate or Discontinuation of Infusion Due to an Adverse Event (Regardless of Adverse Event Causality Assessment)</title>
          <population>Safety Analysis Set</population>
          <units>Infusions</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Infusions With Temporally Associated Adverse Events (AEs) That Began During or Within 1 Hour of Infusion Completion</title>
        <description>Number of infusions with temporally associated AEs with an onset time during or within 1 hour of infusion completion, regardless of causality assessment</description>
        <time_frame>Within 1 hour of infusion completion</time_frame>
        <population>Safety Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>GLASSIA at 0.04 mL/kg/Min + Placebo at 0.2 mL/kg/Min</title>
          </group>
          <group group_id="O2">
            <title>GLASSIA at 0.2 mL/kg/Min + Placebo at 0.04 mL/kg/Min</title>
          </group>
        </group_list>
        <measure>
          <title>Number of Infusions With Temporally Associated Adverse Events (AEs) That Began During or Within 1 Hour of Infusion Completion</title>
          <description>Number of infusions with temporally associated AEs with an onset time during or within 1 hour of infusion completion, regardless of causality assessment</description>
          <population>Safety Analysis Set</population>
          <units>Infusions</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Infusions With Temporally Associated Adverse Events (AEs) That Began During or Within 24 Hours of Completion of an Infusion</title>
        <description>Number of infusions with temporally associated AEs with an onset time during or within 24 hours of infusion completion, regardless of causality assessment</description>
        <time_frame>Within 24 hours of the end of infusion</time_frame>
        <population>Safety Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>GLASSIA at 0.04 mL/kg/Min + Placebo at 0.2 mL/kg/Min</title>
          </group>
          <group group_id="O2">
            <title>GLASSIA at 0.2 mL/kg/Min + Placebo at 0.04 mL/kg/Min</title>
          </group>
        </group_list>
        <measure>
          <title>Number of Infusions With Temporally Associated Adverse Events (AEs) That Began During or Within 24 Hours of Completion of an Infusion</title>
          <description>Number of infusions with temporally associated AEs with an onset time during or within 24 hours of infusion completion, regardless of causality assessment</description>
          <population>Safety Analysis Set</population>
          <units>Infusions</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Infusions With Temporally Associated Adverse Events (AEs) That Began During or Within 72 Hours of Completion of an Infusion</title>
        <description>Number of infusions with temporally associated AEs with an onset time during or within 72 hours of infusion completion, regardless of causality assessment</description>
        <time_frame>Within 72 hours of the end of infusion</time_frame>
        <population>Safety Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>GLASSIA at 0.04 mL/kg/Min + Placebo at 0.2 mL/kg/Min</title>
          </group>
          <group group_id="O2">
            <title>GLASSIA at 0.2 mL/kg/Min + Placebo at 0.04 mL/kg/Min</title>
          </group>
        </group_list>
        <measure>
          <title>Number of Infusions With Temporally Associated Adverse Events (AEs) That Began During or Within 72 Hours of Completion of an Infusion</title>
          <description>Number of infusions with temporally associated AEs with an onset time during or within 72 hours of infusion completion, regardless of causality assessment</description>
          <population>Safety Analysis Set</population>
          <units>Infusions</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Possibly or Probably Related Adverse Events (AEs) That Began During an Infusion</title>
        <description>Number of AEs that occurred during an infusion and were deemed related to study product administration</description>
        <time_frame>Day 1 and Day 15</time_frame>
        <population>Safety Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>GLASSIA at 0.04 mL/kg/Min + Placebo at 0.2 mL/kg/Min</title>
          </group>
          <group group_id="O2">
            <title>GLASSIA at 0.2 mL/kg/Min + Placebo at 0.04 mL/kg/Min</title>
          </group>
        </group_list>
        <measure>
          <title>Number of Possibly or Probably Related Adverse Events (AEs) That Began During an Infusion</title>
          <description>Number of AEs that occurred during an infusion and were deemed related to study product administration</description>
          <population>Safety Analysis Set</population>
          <units>adverse events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Possibly or Probably Related Adverse Events That Occurred Between 72 Hours and 14 Days After Infusion</title>
        <description>Number of AEs that occurred between 72 hours and 14 day following an infusion and were deemed related to study product administration</description>
        <time_frame>72 hours post infusion to 14 days post infusion</time_frame>
        <population>Safety Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>GLASSIA at 0.04 mL/kg/Min + Placebo at 0.2 mL/kg/Min</title>
          </group>
          <group group_id="O2">
            <title>GLASSIA at 0.2 mL/kg/Min + Placebo at 0.04 mL/kg/Min</title>
          </group>
        </group_list>
        <measure>
          <title>Number of Possibly or Probably Related Adverse Events That Occurred Between 72 Hours and 14 Days After Infusion</title>
          <description>Number of AEs that occurred between 72 hours and 14 day following an infusion and were deemed related to study product administration</description>
          <population>Safety Analysis Set</population>
          <units>adverse events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Testing Positive for Hepatitis A Virus (HAV), Hepatitis B Virus (HBV), Hepatitis C Virus (HCV), Parvovirus B19 (PVB19) or Human Immunodeficiency Virus (HIV) Following Treatment With GLASSIA</title>
        <description>Number of participants with seroconversion</description>
        <time_frame>105 days</time_frame>
        <population>Safety Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>All Study Participants</title>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Testing Positive for Hepatitis A Virus (HAV), Hepatitis B Virus (HBV), Hepatitis C Virus (HCV), Parvovirus B19 (PVB19) or Human Immunodeficiency Virus (HIV) Following Treatment With GLASSIA</title>
          <description>Number of participants with seroconversion</description>
          <population>Safety Analysis Set</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>HAV</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HBV</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HCV</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PVB19</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HIV</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Throughout the study period of 105 days per participant</time_frame>
      <group_list>
        <group group_id="E1">
          <title>GLASSIA Infusion Rate- 0.04 mL/kg/Min</title>
          <description>Participants who received simultaneous infusions of:
GLASSIA at 0.04 mL/kg/min
Placebo at 0.2 mL/kg/min</description>
        </group>
        <group group_id="E2">
          <title>GLASSIA Infusion Rate- 0.2 mL/kg/Min</title>
          <description>Participants who received simultaneous infusions of:
GLASSIA at 0.2 mL/kg/min
Placebo at 0.04 mL/kg/min</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (Unspecified)</default_vocab>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back Pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Pain In Extremity</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="30"/>
                <counts group_id="E2" events="5" subjects_affected="3" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>PI may not publish without the prior written consent of Sponsor</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Simultaneous infusion of GLASSIA and placebo did not allow adverse events (AEs) to be unquestionably ascribed to either one. Any observed AE which was assessed by the investigator as related to treatment was conservatively attributed to GLASSIA.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Leman Yel, MD, Medical Director, Biotherapeutics</name_or_title>
      <organization>Baxter Healthcare Corporation</organization>
      <email>leman_yel@baxter.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

